Sign in
Not yet taking people in United StatesPhase 3

Xenon for Neuroprotection During Post-Cardiac Arrest Syndrome in Comatose Survivors of an Out of Hospital Cardiac Arrest

Key facts

Who runs it
Invero Pharma, Inc.
Where
Buffalo, Columbus, Gainesville, Gulfport, Hartford, Houston, Memphis, and Omaha, United StatesSee the 8 sitesAlso in 1 other country, 2 sites
Trial code
Status
Not yet recruiting
Phase
Phase 3
People taking part
1,436 people, planned
Started
Mar 2026
Expected to end
May 2030
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Xenon
Record updated
3 April 2025

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 25 criteriaShow less

Who can take part

  • Age at least 18 years but less than or equal to 80 years
  • Presumed cardiac cause of arrest
  • Sustained (>20 minutes) spontaneous circulation upon arrival in the emergency department
  • No response to verbal commands on arrival to emergency department and prior to randomization (Glasgow Coma Scale score of <8)
  • Attending decision that patient is eligible for TTM

Who cannot take part

  • Traumatic etiology of arrest, defined as concomitant blunt, penetrating, or burn-related injury, or uncontrolled bleeding or exsanguination
  • Bed-bound prior to cardiac arrest
  • Have received an investigational drug, device, or biologic product within 30-days
  • Suspected or known stroke or intracranial hemorrhage
  • Unwitnessed cardiac arrest
  • No-flow (cardiac arrest to initiation of cardiopulmonary resuscitation/defibrillation) time of >10 minutes
  • Unconsciousness before cardiac arrest (cerebral trauma, spontaneous cerebral hemorrhage, intoxication etc.)
  • Known terminal phase of chronic illness
  • Have any condition that would impact the evaluation of modified Rankin Scale (mRS)
  • Having any other clinically significant laboratory abnormality, medical condition (such as intrinsic liver disease or severe chronic obstructive pulmonary disease), or social circumstance that, in the investigator's opinion, makes it inappropriate for the patient to participate in this clinical trial
  • Written do not attempt resuscitation reported to providers before randomization
  • Sustained restoration of spontaneous circulation (ROSC) greater than 30- minutes post-arrest
  • Interval from arrival at the emergency department to randomization for intervention of >4 hours
  • Hypothermia (<30°C core temperature)
  • Coagulopathy
  • Systolic arterial pressure <80 mmHg or mean arterial pressure <60 mmHg lasting more than 30 minutes after ROSC
  • Known pregnancy
  • Hypoxemia (SaO2 <85%) for >15 minutes after ROSC
  • Inability to maintain SaO2 >90% on an FiO2 of 50%
  • Logistically impossible to provide intervention

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

Where in United States

Also in 1 other country, 2 sites

  • University at BuffaloBuffalo, United StatesContact: Robin M. Stein, RN, BSNNot yet recruiting
  • Wexner Medical Center, Ohio State UniversityColumbus, United StatesContact: January Kim, BSNot yet recruiting
  • University of FloridaGainesville, United StatesContact: Clinical Trial Support at Invero PharmaNot yet recruiting
  • Memorial Hospital at GulfportGulfport, United StatesContact: Brandy WilliamsNot yet recruiting
  • Hartford HospitalHartford, United StatesContact: William RomanNot yet recruiting
  • Houston Methodist Research InstituteHouston, United StatesContact: Digant JariwalaNot yet recruiting
  • Baptist Memorial Hospital, Baptist Clinical Research InstituteMemphis, United StatesContact: Mildred JenkinsNot yet recruiting
  • University Nebraska Medical CenterOmaha, United StatesContact: Lace D Sindt, BSNot yet recruiting

About the trial

What the trial wants to find out

XePOHCAS: Prospective, randomized, multicenter interventional trial in adult subjects with out-of-hospital cardiac arrest comparing treatment with standard-of-care post-cardiac arrest intensive care (which is targeted temperature management [TTM]) to xenon by inhalation plus standard-of-care post-cardiac arrest intensive care (including TTM).

The 2 groups in the trial

  • TH/TTMNo study treatment, for comparison

    Protocol-directed standard of care (including TH/TTM) dictated by the 2015 guidelines for Post-Cardiac Arrest Care from the American Heart Association and the European Resuscitation Council. Mechanical Ventilation delivered by individual site-sanctioned ventilator.

  • TH/TTM plus XenonExisting treatment, for comparison

    50% xenon gas in addition to standard of care, including therapeutic hypothermia/targeted temperature management (TH/TTM).

    Treatment: Xenon

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
XePOHCAS - Xenon by Inhalation for Post Out of Hospital Cardiac Arrest Syndrome
Criteria questions
Built from NCT03176186, who can take part
Publications
Record updated
3 April 2025